Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Risk adjusted net present value: What is the current valuation of Annexon's ANX-005?
ANX-005 is a monoclonal antibody commercialized by Annexon, with a leading Phase III program in Guillain-Barre Syndrome. According to Globaldata,...
ANX-005 by Annexon for Guillain-Barre Syndrome: Likelihood of Approval
ANX-005 is under clinical development by Annexon and currently in Phase III for Guillain-Barre Syndrome. According to GlobalData, Phase III...
ANX-005 by Annexon for Amyotrophic Lateral Sclerosis: Likelihood of Approval
ANX-005 is under clinical development by Annexon and currently in Phase II for Amyotrophic Lateral Sclerosis. According to GlobalData, Phase...